First clinical trial on HER-2-negative breast cancer with nintedanib shows promising results
Thursday, September 11, 2014 - 03:32
in Health & Medicine
The experimental drug nintedanib, combined with standard chemotherapy with paclitaxel, causes a total remission of tumors in 50 percent of patients suffering from early HER-2-negative breast cancer, the most common type of breast cancer.